Myricx Bio

Myricx Bio is a UK-based biotechnology company dedicated to developing innovative antibody drug conjugates (ADCs) that target unmet medical needs in oncology, focusing on enhancing cancer treatment efficacy. Founded in 2019 and headquartered in London, UK, Myricx Bio specializes in the development of antibody drug conjugates (ADCs) designed to improve cancer care. The company has successfully raised GBP 90 million in Series A funding as of July 2024, with prominent investors such as Novo Holdings and Abingworth participating in this round. Andrew Bell, the founder of Myricx Bio, has a background that includes previous entrepreneurial ventures in the biotech industry.

Myricx Bio specializes in the development of a novel class of antibody drug conjugates (ADCs) that utilize inhibitors of N-myristoyltransferases (NMT) as their key payloads. These innovative ADCs are designed to address significant unmet needs in oncology, providing targeted therapy for various solid tumor-associated antigens and cancer cell types. Myricx Bio's ADCs aim to enhance efficacy while maintaining safety, demonstrated by their strong preclinical performance. The company focuses on North America and Europe, partnering with pharmaceutical companies and research institutions to advance cancer treatments, with oncologists and healthcare providers as the primary end users of these therapies.

Myricx Bio engages in B2B transactions, primarily through partnerships with pharmaceutical companies and research institutions. These collaborations involve licensing agreements, where Myricx Bio provides its proprietary ADC technology for clinical development and commercialization. Revenue may come from milestone payments linked to the progress of ADC candidates in clinical trials, as well as royalties on sales once products are commercialized. The structure of these transactions could include fixed payments upon achieving regulatory milestones and ongoing royalties based on product sales.

The company's flagship products leverage their ADC technology in oncology, underlining their commitment to innovative cancer therapies. In July 2024, Myricx Bio successfully raised GBP 90 million in Series A funding, co-led by Novo Holdings and Abingworth. This funding will support the development of their platform and product advancement. The company plans to expand its product offerings, with new ADCs targeting specific cancer therapies expected to enter development soon.

Additionally, Myricx Bio aims to broaden its market reach in North America and Europe, seeking collaborations with pharmaceutical firms and research institutions to enhance their innovation in cancer treatment. The anticipated advancements will be bolstered by the recent funding, enabling the firm to pursue its growth strategy effectively.